A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

A year-long clinical trial has found that Ambroxol, a cough syrup commonly sold across Europe, could potentially slow the ...

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

About half of those diagnosed with Parkinson's develop dementia within 10 years, profoundly affecting patients, families and the health care system ...

A landmark study by London researchers investigating the use of a cough medicine called Ambroxo to slow the progression of ...